API | tositumomab

tositumomab (Bexxar) Report issue

Biologics mAb ADC Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab, for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
tositumomab

More Chemistry

Pharmacology

Mechanisms of Action:
- B-lymphocyte antigen CD20 (Homo sapiens) ^UniProt
- B-lymphocyte antigen CD20 (Homo sapiens) ^UniProt
- B-lymphocyte antigen CD20 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: 131-iodine
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Organizations (24)

Research & Development (24)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (2)

Lymphoma, Follicular (approved 2004)

Lymphoma, Non-Hodgkin (approved 2004)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Hodgkin Disease (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 33
# of Trial Organizations: 24

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue